Competitor MindWalk Reports 52% Q3 Revenue Growth, Lands LensAI Contract
RXRX•MindWalk Holdings reported fiscal Q3 revenue of CAD4.2 million, up 52% year-over-year with U.S. revenue doubling, and secured its first recurring one-year LensAI platform contract. Its proprietary biological context layer, encompassing 660 million patterns and 25 billion relationships, aims to reduce AI hallucinations and may pressure Recursion Pharmaceuticals to reinforce its data integration in drug discovery.
1. MindWalk Q3 Financial Results
For the quarter ended January 31, 2026, MindWalk reported CA$4.2 million in revenue, marking a 52% increase year-over-year and doubling U.S. sales. The company also announced its first recurring one-year contract for its LensAI platform, signaling a shift toward predictable, platform-based revenue.
2. Biological Context Layer Technology
MindWalk’s HYFT® Technology underpins its strategy, uniting 660 million curated biological patterns with 25 billion defined relationships. This context layer connects sequences, structures, functions and literature to provide a reliable foundation for AI reasoning and minimize costly model hallucinations.
3. Product Offerings and Client Adoption
MindWalk markets two core products: ReefIQ™, which prepares fragmented discovery data for AI workflows, and LensAI™, the application layer for target discovery and decision support. The newly signed LensAI contract represents the company’s first recurring platform-revenue deal and a template for future enterprise engagements.
4. Competitive Implications for Recursion Pharmaceuticals
MindWalk’s emphasis on curated biological context rather than model size may intensify pressure on Recursion Pharmaceuticals to enhance its own data integration and curation capabilities. Investors will watch whether Recursion adapts its AI-driven discovery platform to mitigate similar risks.
